Valuation: Krystal Biotech, Inc.

Market Cap 9.81B 8.5B 7.94B 7.26B 13.68B 936B 13.89B 93.13B 36.54B 468B 36.85B 36.05B 1,560B P/E 2026 *
44.5x
P/E 2027 * 35.7x
Enterprise Value 9.81B 8.5B 7.94B 7.26B 13.68B 936B 13.89B 93.13B 36.54B 468B 36.85B 36.05B 1,560B EV / Sales 2026 *
19.5x
EV / Sales 2027 * 15x
Free-Float
89.07%
Yield 2026 *
-
Yield 2027 * -
1 day+1.57%
1 week+6.09%
Current month-2.79%
1 month-9.35%
3 months+8.47%
6 months+22.49%
Current year+34.50%
1 week 316.15
Extreme 316.1544
332.73
1 month 297.02
Extreme 297.02
369
Current year 235.6
Extreme 235.605
382.54
1 year 136.73
Extreme 136.73
382.54
3 years 93.95
Extreme 93.95
382.54
5 years 38.86
Extreme 38.8563
382.54
10 years 8.03
Extreme 8.03
382.54
Manager TitleAgeSince
Chief Operating Officer 61 2016-04-14
Chief Executive Officer 61 2016-04-14
Investor Relations Contact - -
Director TitleAgeSince
Chairman 61 2016-04-14
Director/Board Member 61 2016-04-14
Director/Board Member 60 2016-10-31
Date Insider Type Main position Quantity % Market Cap.
3/1/26 Other

EVP, Head of International

51,478 0.1761%
3/1/26 Other

General Counsel

68,165 0.2332%
2/27/26 Fiscal year

Founder

38,556 0.1330%
Change 5-day change 1-year change 3-year change Capi.($)
+1.57%+6.09%+139.14%+174.56% 9.81B
+3.02%+6.43%+43.53%+1.90% 80.69B
+0.84%+10.26%-0.15%+27.24% 51.22B
+0.31%+1.67%+22.01%+176.54% 49.58B
+2.87%+8.18%-48.46%-49.18% 45.5B
-0.39%+2.63%+58.51%-23.02% 30.6B
+0.82%+2.63%+55.06%+85.54% 24.64B
+1.08%+8.47%+128.98%-40.36% 23.88B
-1.80%+13.14%+6.63%+202.17% 21.59B
+14.10%+42.49%+5.21%+848.43% 17.09B
Average +2.62%+6.75%+41.05%+140.38% 35.46B
Weighted average by Cap. +2.13%+5.60%+28.81%+82.01%

Financials

2026 *2027 *
Net sales 504M 437M 408M 373M 703M 48.11B 714M 4.79B 1.88B 24.07B 1.89B 1.85B 80.16B 655M 567M 530M 484M 912M 62.45B 927M 6.21B 2.44B 31.24B 2.46B 2.4B 104B
Net income 232M 201M 188M 172M 324M 22.14B 329M 2.2B 864M 11.08B 872M 853M 36.89B 307M 266M 248M 227M 428M 29.29B 435M 2.91B 1.14B 14.65B 1.15B 1.13B 48.8B
Net Debt - -
Logo Krystal Biotech, Inc.
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Employees
295
Date Price Change Volume
26-08-10 US$331.59 +1.57% 151,951
26-08-07 US$326.45 +1.17% 160,038
26-08-06 US$322.69 -0.95% 206,285
26-08-05 US$325.78 +0.31% 324,612
26-08-04 US$324.77 +3.90% 534,611
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
331.59USD
Average target price
382.86USD
Spread / Average Target
+15.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KRYS Stock